Pharma and Biotech Clinical Trial Leaders to Convene for Third Annual DrugDev Summit to Promote Collaboration, Technology Innovation, Engaged Sites, and More Informed Patients
Pharma and Biotech Clinical Trial Leaders to Convene for Third Annual DrugDev Summit to Promote Collaboration, Technology Innovation, Engaged Sites, and More Informed Patients
More than 125 innovative sponsors, CROs, sites and patients will gather to exchange best practices, share case studies, preview new DrugDev technology, network and strategize to drive improvement in global clinical trials
London, UK and Philadelphia, PA – DrugDev, a QuintilesIMS company, will gather the most innovative minds in pharma and biotech at the third annual DrugDev Summit, November 7-8, 2017 in Philadelphia, PA. The DrugDev Summit is a two-day collaborative conference that brings together the world’s most progressive clinical research leaders for best practice case studies, keynote presentations, lively breakout sessions, hands-on training, and previews of new DrugDev technology-based solutions.
Featuring a client-driven agenda and highlighted by inspiring industry keynotes (announcements to come soon), last year’s Summit welcomed expert speakers from host company Merck, Janssen, Pfizer, Novartis, Eli Lilly, ICON, Boehringer-Ingelheim, Incyte, INC Research, Alkermes, BioMarin, Chesapeake IRB, Radiant Research, and Emerson Clinical Research Institute. Register for the 2017 DrugDev Summit here.
“The 2016 DrugDev Summit was a very engaging event,” said Dawn Furey, Executive Director/Head, Global Operations, at Merck. “To be honest, I didn’t think I would stay for the entire two days given my competing priorities, but I couldn’t step away. It was great.”
DrugDev expects more than 125 clinical leaders to attend this year’s Summit, which promotes three pillars of clinical research optimization – collaboration, standardization, and a beautiful technology experience – to transform the quality, transparency and efficiency of clinical trials. Summit participants gain actionable advice and inspiration from sponsors, sites and patients as they network in an organized yet congenial setting. The invitation-only event is complimentary for all sponsors, CROs and sites using DrugDev technology on nearly 2,000 clinical programs.
DrugDev President and CEO Ibs Mahmood said, “Imagine the best minds in pharma and biotech gathering together, all fearless in their dedication to changing everything to speed the delivery of many more new treatments to millions of patients, and there you have the DrugDev Summit. I’m always awed by the brilliant insights and the interactions among professionals who just want to get it done for patients. I expect this year to be especially exciting as customers share their experiences standardizing on the DrugDev Spark™ unified suite across entire, massive clinical programs, and I’m very much looking forward to seeing what they can accomplish next.”
Email summit@drugdev.com with questions or for more information.
About DrugDev
DrugDev, a QuintilesIMS company, helps the world do more trials through industry-wide collaboration, standardization and a beautiful technology experience. DrugDev Spark™, the unified clinical operations suite, is comprised of proven solutions used by 100 sponsors and CROs on nearly 2,000 clinical trials to transform the quality and efficiency of clinical trials from startup through closeout. DrugDev Spark is powered by the DrugDev Golden Number, the award-winning universal identifier for global site facilities and investigators used by TransCelerate and the Investigator Databank. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs trust DrugDev by scheduling a demo of DrugDev Spark at drugdev.com.